Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 174


IL-6 Signaling Blockade during CD40-Mediated Immune Activation Favors Antitumor Factors by Reducing TGF-β, Collagen Type I, and PD-L1/PD-1.

Eriksson E, Milenova I, Wenthe J, Moreno R, Alemany R, Loskog A.

J Immunol. 2019 Jan 7. pii: ji1800717. doi: 10.4049/jimmunol.1800717. [Epub ahead of print]


CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge.

Guedan S, Alemany R.

Front Immunol. 2018 Oct 23;9:2460. doi: 10.3389/fimmu.2018.02460. eCollection 2018. Review.


Bioselection Reveals miR-99b and miR-485 as Enhancers of Adenoviral Oncolysis in Pancreatic Cancer.

Rovira-Rigau M, Raimondi G, Marín MÁ, Gironella M, Alemany R, Fillat C.

Mol Ther. 2019 Jan 2;27(1):230-243. doi: 10.1016/j.ymthe.2018.09.016. Epub 2018 Sep 27.


Enhanced Antitumor Efficacy of Oncolytic Adenovirus-loaded Menstrual Blood-derived Mesenchymal Stem Cells in Combination with Peripheral Blood Mononuclear Cells.

Moreno R, Fajardo CA, Farrera-Sal M, Perisé-Barrios AJ, Morales-Molina A, Al-Zaher AA, García-Castro J, Alemany R.

Mol Cancer Ther. 2019 Jan;18(1):127-138. doi: 10.1158/1535-7163.MCT-18-0431. Epub 2018 Oct 15.


A Phase 1 Trial of Oncolytic Adenovirus ICOVIR-5 Administered Intravenously to Cutaneous and Uveal Melanoma Patients.

García M, Moreno R, Gil-Martin M, Cascallò M, de Olza MO, Cuadra C, Piulats JM, Navarro V, Domenech M, Alemany R, Salazar R.

Hum Gene Ther. 2018 Nov 13. doi: 10.1089/hum.2018.107. [Epub ahead of print]


A phase I trial of oncolytic adenovirus ICOVIR-5 administered intravenously to melanoma patients.

Garcia M, Moreno R, Gil M, Cascallo M, de Olza MO, Cuadra C, Piulat JM, Navarro V, Domenech M, Alemany R, Salazar R.

Hum Gene Ther Clin Dev. 2018 Sep 18. doi: 10.1089/humc.2018.107. [Epub ahead of print]


Nilotinib as Coadjuvant Treatment with Doxorubicin in Patients with Sarcomas: A Phase I Trial of the Spanish Group for Research on Sarcoma.

Alemany R, Moura DS, Redondo A, Martinez-Trufero J, Calabuig S, Saus C, Obrador-Hevia A, Ramos R, Villar VH, Valverde C, Vaz MA, Medina J, Felipe-Abrio I, Hindi N, Taron M, Martin-Broto J.

Clin Cancer Res. 2018 Nov 1;24(21):5239-5249. doi: 10.1158/1078-0432.CCR-18-0851. Epub 2018 Jul 23.


Remission of Spontaneous Canine Tumors after Systemic Cellular Viroimmunotherapy.

Cejalvo T, Perisé-Barrios AJ, Del Portillo I, Laborda E, Rodriguez-Milla MA, Cubillo I, Vázquez F, Sardón D, Ramirez M, Alemany R, Del Castillo N, García-Castro J.

Cancer Res. 2018 Sep 1;78(17):4891-4901. doi: 10.1158/0008-5472.CAN-17-3754. Epub 2018 Jul 10.


Evidence of Anti-tumoral Efficacy in an Immune Competent Setting with an iRGD-Modified Hyaluronidase-Armed Oncolytic Adenovirus.

Al-Zaher AA, Moreno R, Fajardo CA, Arias-Badia M, Farrera M, de Sostoa J, Rojas LA, Alemany R.

Mol Ther Oncolytics. 2018 Jan 31;8:62-70. doi: 10.1016/j.omto.2018.01.003. eCollection 2018 Mar 30.


Antitumor-specific T-cell responses induced by oncolytic adenovirus ONCOS-102 (AdV5/3-D24-GM-CSF) in peritoneal mesothelioma mouse model.

Kuryk L, Møller AW, Garofalo M, Cerullo V, Pesonen S, Alemany R, Jaderberg M.

J Med Virol. 2018 Oct;90(10):1669-1673. doi: 10.1002/jmv.25229. Epub 2018 Jun 11.


Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus-Driven Production of a Bispecific T-cell Engager.

Wing A, Fajardo CA, Posey AD Jr, Shaw C, Da T, Young RM, Alemany R, June CH, Guedan S.

Cancer Immunol Res. 2018 May;6(5):605-616. doi: 10.1158/2326-6066.CIR-17-0314. Epub 2018 Mar 27.


Wnt Signaling Inhibition Promotes Apoptosis in Sarcomas-Response.

Martinez-Font E, Vögler O, Alemany R, Obrador-Hevia A.

Mol Cancer Ther. 2017 Oct;16(10):2325. doi: 10.1158/1535-7163.MCT-17-0567. No abstract available.


Silicon Nitride Photonic Integration Platforms for Visible, Near-Infrared and Mid-Infrared Applications.

Muñoz P, Micó G, Bru LA, Pastor D, Pérez D, Doménech JD, Fernández J, Baños R, Gargallo B, Alemany R, Sánchez AM, Cirera JM, Mas R, Domínguez C.

Sensors (Basel). 2017 Sep 12;17(9). pii: E2088. doi: 10.3390/s17092088.


Human Menstrual Blood-Derived Mesenchymal Stem Cells as Potential Cell Carriers for Oncolytic Adenovirus.

Moreno R, Rojas LA, Villellas FV, Soriano VC, García-Castro J, Fajardo CA, Alemany R.

Stem Cells Int. 2017;2017:3615729. doi: 10.1155/2017/3615729. Epub 2017 Jul 11.


Shaping the Tumor Stroma and Sparking Immune Activation by CD40 and 4-1BB Signaling Induced by an Armed Oncolytic Virus.

Eriksson E, Milenova I, Wenthe J, Ståhle M, Leja-Jarblad J, Ullenhag G, Dimberg A, Moreno R, Alemany R, Loskog A.

Clin Cancer Res. 2017 Oct 1;23(19):5846-5857. doi: 10.1158/1078-0432.CCR-17-0285. Epub 2017 May 23.


Mesenchymal stem cell carriers enhance antitumor efficacy of oncolytic adenoviruses in an immunocompetent mouse model.

Rincón E, Cejalvo T, Kanojia D, Alfranca A, Rodríguez-Milla MÁ, Gil Hoyos RA, Han Y, Zhang L, Alemany R, Lesniak MS, García-Castro J.

Oncotarget. 2017 Jul 11;8(28):45415-45431. doi: 10.18632/oncotarget.17557.


Disruption of TCF/β-Catenin Binding Impairs Wnt Signaling and Induces Apoptosis in Soft Tissue Sarcoma Cells.

Martinez-Font E, Felipe-Abrio I, Calabuig-Fariñas S, Ramos R, Terrasa J, Vögler O, Alemany R, Martín-Broto J, Obrador-Hevia A.

Mol Cancer Ther. 2017 Jun;16(6):1166-1176. doi: 10.1158/1535-7163.MCT-16-0585. Epub 2017 Mar 14.


A NOTCH-sensitive uPAR-regulated oncolytic adenovirus effectively suppresses pancreatic tumor growth and triggers synergistic anticancer effects with gemcitabine and nab-paclitaxel.

Mato-Berciano A, Raimondi G, Maliandi MV, Alemany R, Montoliu L, Fillat C.

Oncotarget. 2017 Apr 4;8(14):22700-22715. doi: 10.18632/oncotarget.15169.


Oncolytic Adenoviral Delivery of an EGFR-Targeting T-cell Engager Improves Antitumor Efficacy.

Fajardo CA, Guedan S, Rojas LA, Moreno R, Arias-Badia M, de Sostoa J, June CH, Alemany R.

Cancer Res. 2017 Apr 15;77(8):2052-2063. doi: 10.1158/0008-5472.CAN-16-1708. Epub 2017 Jan 31.


Activation of myeloid and endothelial cells by CD40L gene therapy supports T-cell expansion and migration into the tumor microenvironment.

Eriksson E, Moreno R, Milenova I, Liljenfeldt L, Dieterich LC, Christiansson L, Karlsson H, Ullenhag G, Mangsbo SM, Dimberg A, Alemany R, Loskog A.

Gene Ther. 2017 Feb;24(2):92-103. doi: 10.1038/gt.2016.80. Epub 2016 Dec 1.


Adenovirus coxsackie adenovirus receptor-mediated binding to human erythrocytes does not preclude systemic transduction.

Rojas LA, Moreno R, Calderón H, Alemany R.

Cancer Gene Ther. 2016 Dec;23(12):411-414. doi: 10.1038/cgt.2016.50. Epub 2016 Oct 21.


Albumin-binding adenoviruses circumvent pre-existing neutralizing antibodies upon systemic delivery.

Rojas LA, Condezo GN, Moreno R, Fajardo CA, Arias-Badia M, San Martín C, Alemany R.

J Control Release. 2016 Sep 10;237:78-88. doi: 10.1016/j.jconrel.2016.07.004. Epub 2016 Jul 4.


Correction: Characterization of the Antiglioma Effect of the Oncolytic Adenovirus VCN-01.

Vera B, Martínez-Vélez N, Xipell E, Acanda de la Rocha A, Patiño-García A, Castresana JS, Gonzalez-Huarriz M, Cascallo M, Alemany R, Alonso MM.

PLoS One. 2016 Jun 9;11(6):e0157619. doi: 10.1371/journal.pone.0157619. eCollection 2016.


Down-Regulation of AKT Signalling by Ursolic Acid Induces Intrinsic Apoptosis and Sensitization to Doxorubicin in Soft Tissue Sarcoma.

Villar VH, Vögler O, Barceló F, Martín-Broto J, Martínez-Serra J, Ruiz-Gutiérrez V, Alemany R.

PLoS One. 2016 May 24;11(5):e0155946. doi: 10.1371/journal.pone.0155946. eCollection 2016.


Randomized Phase II Study of Trabectedin and Doxorubicin Compared With Doxorubicin Alone as First-Line Treatment in Patients With Advanced Soft Tissue Sarcomas: A Spanish Group for Research on Sarcoma Study.

Martin-Broto J, Pousa AL, de Las Peñas R, García Del Muro X, Gutierrez A, Martinez-Trufero J, Cruz J, Alvarez R, Cubedo R, Redondo A, Maurel J, Carrasco JA, López-Martin JA, Sala Á, Meana JA, Ramos R, Martinez-Serra J, Lopez-Guerrero JA, Sevilla I, Balaña C, Vaz Á, De Juan A, Alemany R, Poveda A.

J Clin Oncol. 2016 Jul 1;34(19):2294-302. doi: 10.1200/JCO.2015.65.3329. Epub 2016 May 16.


Joint Modelling of Survival and Emergency Medical Care Usage in Spanish Insureds Aged 65+.

Piulachs X, Alemany R, Guillen M.

PLoS One. 2016 Apr 13;11(4):e0153234. doi: 10.1371/journal.pone.0153234. eCollection 2016.


Mutanome and expression of immune response genes in microsatellite stable colon cancer.

Sanz-Pamplona R, Gil-Hoyos R, López-Doriga A, Alonso MH, Aussó S, Molleví DG, Santos C, Sanjuán X, Salazar R, Alemany R, Moreno V.

Oncotarget. 2016 Apr 5;7(14):17711-25. doi: 10.18632/oncotarget.7293.


Characterization of the Antiglioma Effect of the Oncolytic Adenovirus VCN-01.

Vera B, Martínez-Vélez N, Xipell E, Acanda de la Rocha A, Patiño-García A, Saez-Castresana J, Gonzalez-Huarriz M, Cascallo M, Alemany R, Alonso MM.

PLoS One. 2016 Jan 25;11(1):e0147211. doi: 10.1371/journal.pone.0147211. eCollection 2016. Erratum in: PLoS One. 2016;11(6):e0157619.


Highlights of 8th Biennial Congress of the Spanish Society of Gene and Cell Therapy.

Alemany R, Izeta A, Garcia-Sancho J.

Hum Gene Ther. 2016 Jan;27(1):92-3. doi: 10.1089/hum.2015.29015.ral. No abstract available.


Influence of carrier cells on the clinical outcome of children with neuroblastoma treated with high dose of oncolytic adenovirus delivered in mesenchymal stem cells.

Melen GJ, Franco-Luzón L, Ruano D, González-Murillo Á, Alfranca A, Casco F, Lassaletta Á, Alonso M, Madero L, Alemany R, García-Castro J, Ramírez M.

Cancer Lett. 2016 Feb 28;371(2):161-70. doi: 10.1016/j.canlet.2015.11.036. Epub 2015 Dec 3.


The Oncolytic Adenovirus VCN-01 as Therapeutic Approach Against Pediatric Osteosarcoma.

Martínez-Vélez N, Xipell E, Vera B, Acanda de la Rocha A, Zalacain M, Marrodán L, Gonzalez-Huarriz M, Toledo G, Cascallo M, Alemany R, Patiño A, Alonso MM.

Clin Cancer Res. 2016 May 1;22(9):2217-25. doi: 10.1158/1078-0432.CCR-15-1899. Epub 2015 Nov 24.


Hepatocyte Heparan Sulfate Is Required for Adeno-Associated Virus 2 but Dispensable for Adenovirus 5 Liver Transduction In Vivo.

Zaiss AK, Foley EM, Lawrence R, Schneider LS, Hoveida H, Secrest P, Catapang AB, Yamaguchi Y, Alemany R, Shayakhmetov DM, Esko JD, Herschman HR.

J Virol. 2015 Oct 21;90(1):412-20. doi: 10.1128/JVI.01939-15. Print 2016 Jan 1.


RG7112, a small-molecule inhibitor of MDM2, enhances trabectedin response in soft tissue sarcomas.

Obrador-Hevia A, Martinez-Font E, Felipe-Abrio I, Calabuig-Fariñas S, Serra-Sitjar M, López-Guerrero JA, Ramos R, Alemany R, Martín-Broto J.

Cancer Invest. 2015;33(9):440-50. doi: 10.3109/07357907.2015.1064534. Epub 2015 Aug 17.


RG7112, a Small-Molecule Inhibitor of MDM2, Enhances Trabectedin Response in Soft Tissue Sarcomas.

Obrador-Hevia A, Martinez-Font E, Felipe-Abrio I, Calabuig-Fariñas S, Serra-Sitjar M, López-Guerrero JA, Ramos R, Alemany R, Martín-Broto J.

Cancer Invest. 2015 Aug 17. [Epub ahead of print]


Mesenchymal Stromal Cells for Linked Delivery of Oncolytic and Apoptotic Adenoviruses to Non-small-cell Lung Cancers.

Hoyos V, Del Bufalo F, Yagyu S, Ando M, Dotti G, Suzuki M, Bouchier-Hayes L, Alemany R, Brenner MK.

Mol Ther. 2015 Sep;23(9):1497-506. doi: 10.1038/mt.2015.110. Epub 2015 Jun 18.


Insertion of exogenous epitopes in the E3-19K of oncolytic adenoviruses to enhance TAP-independent presentation and immunogenicity.

Rodríguez-García A, Svensson E, Gil-Hoyos R, Fajardo CA, Rojas LA, Arias-Badia M, Loskog AS, Alemany R.

Gene Ther. 2015 Jul;22(7):596-601. doi: 10.1038/gt.2015.41. Epub 2015 May 21.


Delivery of an adenovirus vector plasmid by ultrapure oligochitosan based polyplexes.

Agirre M, Zarate J, Ojeda E, Puras G, Rojas LA, Alemany R, Pedraz JL.

Int J Pharm. 2015 Feb 20;479(2):312-9. doi: 10.1016/j.ijpharm.2014.12.062. Epub 2014 Dec 27.


Safety and efficacy of VCN-01, an oncolytic adenovirus combining fiber HSG-binding domain replacement with RGD and hyaluronidase expression.

Rodríguez-García A, Giménez-Alejandre M, Rojas JJ, Moreno R, Bazan-Peregrino M, Cascalló M, Alemany R.

Clin Cancer Res. 2015 Mar 15;21(6):1406-18. doi: 10.1158/1078-0432.CCR-14-2213. Epub 2014 Nov 12.


Encapsulated stem cells loaded with hyaluronidase-expressing oncolytic virus for brain tumor therapy.

Martinez-Quintanilla J, He D, Wakimoto H, Alemany R, Shah K.

Mol Ther. 2015 Jan;23(1):108-18. doi: 10.1038/mt.2014.204. Epub 2014 Oct 29.


Combining oncolytic virotherapy and cytotoxic therapies to fight cancer.

Fillat C, Maliandi MV, Mato-Berciano A, Alemany R.

Curr Pharm Des. 2014;20(42):6513-21. Review.


ORCA-010, a novel potency-enhanced oncolytic adenovirus, exerts strong antitumor activity in preclinical models.

Dong W, van Ginkel JW, Au KY, Alemany R, Meulenberg JJ, van Beusechem VW.

Hum Gene Ther. 2014 Oct;25(10):897-904. doi: 10.1089/hum.2013.229. Epub 2014 Sep 17.


A genetic fiber modification to achieve matrix-metalloprotease-activated infectivity of oncolytic adenovirus.

José A, Rovira-Rigau M, Luna J, Giménez-Alejandre M, Vaquero E, García de la Torre B, Andreu D, Alemany R, Fillat C.

J Control Release. 2014 Oct 28;192:148-56. doi: 10.1016/j.jconrel.2014.07.008. Epub 2014 Jul 15.


Fluorescence resonance energy transfer-based real-time polymerase chain reaction method without DNA extraction for the genotyping of F5, F2, F12, MTHFR, and HFE.

Martinez-Serra J, Robles J, Nicolàs A, Gutierrez A, Ros T, Amat JC, Alemany R, Vögler O, Abelló A, Noguera A, Besalduch J.

J Blood Med. 2014 Jun 25;5:99-106. doi: 10.2147/JBM.S64976. eCollection 2014.


iRGD tumor-penetrating peptide-modified oncolytic adenovirus shows enhanced tumor transduction, intratumoral dissemination and antitumor efficacy.

Puig-Saus C, Rojas LA, Laborda E, Figueras A, Alba R, Fillat C, Alemany R.

Gene Ther. 2014 Aug;21(8):767-74. doi: 10.1038/gt.2014.52. Epub 2014 Jun 19.


Adenovirus-based vaccines for fighting infectious diseases and cancer: progress in the field.

Majhen D, Calderon H, Chandra N, Fajardo CA, Rajan A, Alemany R, Custers J.

Hum Gene Ther. 2014 Apr;25(4):301-17. doi: 10.1089/hum.2013.235. Epub 2014 Mar 31. Review.


Oncolytic Adenoviruses in Cancer Treatment.

Alemany R.

Biomedicines. 2014 Feb 21;2(1):36-49. doi: 10.3390/biomedicines2010036. Review.


Circumventing antivector immunity: potential use of nonhuman adenoviral vectors.

Lopez-Gordo E, Podgorski II, Downes N, Alemany R.

Hum Gene Ther. 2014 Apr;25(4):285-300. doi: 10.1089/hum.2013.228. Epub 2014 Mar 25. Review.


Oleanolic and maslinic acid sensitize soft tissue sarcoma cells to doxorubicin by inhibiting the multidrug resistance protein MRP-1, but not P-glycoprotein.

Villar VH, Vögler O, Barceló F, Gómez-Florit M, Martínez-Serra J, Obrador-Hevia A, Martín-Broto J, Ruiz-Gutiérrez V, Alemany R.

J Nutr Biochem. 2014 Apr;25(4):429-38. doi: 10.1016/j.jnutbio.2013.12.003. Epub 2013 Dec 31.


A pRb-responsive, RGD-modified, and hyaluronidase-armed canine oncolytic adenovirus for application in veterinary oncology.

Laborda E, Puig-Saus C, Rodriguez-García A, Moreno R, Cascalló M, Pastor J, Alemany R.

Mol Ther. 2014 May;22(5):986-98. doi: 10.1038/mt.2014.7. Epub 2014 Jan 22.


The combination of i-leader truncation and gemcitabine improves oncolytic adenovirus efficacy in an immunocompetent model.

Puig-Saus C, Laborda E, Rodríguez-García A, Cascalló M, Moreno R, Alemany R.

Cancer Gene Ther. 2014 Feb;21(2):68-73. doi: 10.1038/cgt.2013.85. Epub 2014 Jan 17.


Supplemental Content

Loading ...
Support Center